Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.34 USD

133.34
1,015,004

+0.26 (0.20%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $133.39 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.

Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.

Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

by Zacks Equity Research

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

Sarepta Therapeutics (SRPT) Moves 8.4% Higher: Will This Strength Last?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Madeleine Johnson headshot

Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday

by Madeleine Johnson

Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.

Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -4.48% and 4.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down

by Zacks Equity Research

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q4 revenues increase year over year. The company is progressing well with its pipeline.

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -20.00% and 1.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Sarepta Therapeutics (SRPT) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.

Will Sarepta's (SRPT) Overdependence on Exondys 51 Hurt?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on Exondys 51 for near-term growth is a concern.

Sarepta (SRPT) Inks New Gene Editing Research Collaboration

by Zacks Equity Research

Sarepta (SRPT) signs agreement with Genevant to develop lipid nanoparticle-based gene editing medicines targeting neuromuscular indications.

Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session

by Zacks Equity Research

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy

by Zacks Equity Research

Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.

Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate

by Zacks Equity Research

Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.

Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051

by Zacks Equity Research

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Sarepta Therapeutics (SRPT) Up 8.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA

by Zacks Equity Research

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Sarepta (SRPT) Q3 revenues increase year over year.